The NRF2 Paradox
One of the most important discoveries in NRF2 research is its "Janus-faced duality" — a term coined by leading researcher Donna D. Zhang in her landmark 2025 Nature Reviews Drug Discovery paper. In normal cells, NRF2 is unequivocally protective, preventing DNA damage and reducing cancer risk. However, in established cancers, constitutively elevated NRF2 can become the tumor's greatest ally.
NRF2 as Cancer Protector
In healthy cells, NRF2 activation:
- Detoxifies carcinogens through Phase II enzyme induction
- Reduces DNA damage from reactive oxygen species (ROS)
- Maintains genomic stability through base excision repair support
- Eliminates environmental carcinogens (tobacco smoke, industrial chemicals)
Epidemiological studies consistently show that diets rich in NRF2-activating cruciferous vegetables reduce cancer risk by 20-40%.
NRF2 as Tumor Promoter
When cancer cells acquire constitutive NRF2 activation — through gain-of-function NRF2 mutations, loss-of-function KEAP1 mutations, or epigenetic changes — the consequences are profound:
- Chemotherapy resistance: NRF2 upregulates drug efflux pumps and detoxification enzymes
- Immunotherapy resistance: NRF2-activated tumors show impaired responses to anti-PD1 therapy
- Ferroptosis evasion: NRF2 prevents the iron-dependent cell death that therapies try to induce
- Metabolic advantage: Enhanced glucose metabolism and pentose phosphate pathway flux
- Immune evasion: NRF2-activated tumor-associated macrophages suppress anti-tumor immunity
Therapeutic Implications
This duality means NRF2-targeted therapy must be context-specific:
- Cancer prevention: NRF2 activation through diet and supplements is beneficial
- Active cancer treatment: NRF2 inhibition may overcome therapy resistance
- Combination approaches: CRISPR gene editing now allows tumor-specific NRF2 targeting
Research published in 2025 by Banas and Kmiec demonstrated CRISPR-based selective NRF2 disruption in cancer cells, restoring chemotherapy sensitivity while leaving normal cells unaffected — a potential breakthrough for context-specific NRF2 modulation.